Elena RodrÃ-guez-SÃ;nchez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4799357/publications.pdf

Version: 2024-02-01

24 papers 241 citations

8 h-index 1058476 14 g-index

24 all docs

24 docs citations

times ranked

24

271 citing authors

#	Article	IF	CITATIONS
1	Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes. Nephrology Dialysis Transplantation, 2019, 34, 1864-1875.	0.7	40
2	An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. Frontiers in Physiology, 2021, 12, 632260.	2.8	39
3	Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca ²⁺ handling. British Journal of Pharmacology, 2020, 177, 4701-4719.	5.4	24
4	Resistant hypertension: new insights and therapeutic perspectives. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 188-193.	3.0	18
5	Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9–Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA. Frontiers in Immunology, 2017, 8, 853.	4.8	14
6	Oxidative Status before and after Renal Replacement Therapy: Differences between Conventional High Flux Hemodialysis and on-Line Hemodiafiltration. Nutrients, 2019, 11, 2809.	4.1	13
7	Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology. Antioxidants and Redox Signaling, 2021, 35, 602-617.	5. 4	9
8	Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals. Scientific Reports, 2018, 8, 4802.	3.3	8
9	Lifetime cardiovascular risk is associated with a multimarker score of systemic oxidative status in young adults independently of traditional risk factors. Translational Research, 2019, 212, 54-66.	5.0	8
10	Asociación entre disminución de la función renal y actividad metaloproteinasa-9 en el paciente hipertenso. Nefrologia, 2019, 39, 184-191.	0.4	8
11	Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients. Transplantation, 2020, 104, 2599-2608.	1.0	8
12	Oxidized Low-Density Lipoprotein Associates with Ventricular Stress in Young Adults and Triggers Intracellular Ca2+ Alterations in Adult Ventricular Cardiomyocytes. Antioxidants, 2020, 9, 1213.	5.1	7
13	The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23. BMC Medicine, 2022, 20, 14.	5.5	7
14	Unilateral Acute Renal Ischemia-Reperfusion Injury Induces Cardiac Dysfunction through Intracellular Calcium Mishandling. International Journal of Molecular Sciences, 2022, 23, 2266.	4.1	7
15	Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. Nefrologia, 2019, 39, 184-191.	0.4	6
16	Novel molecular plasma signatures on cardiovascular disease can stratify patients throughout life. Journal of Proteomics, 2020, 222, 103816.	2.4	5
17	Interplay between mineral bone disorder and cardiac damage in acute kidney injury: from Ca2+ mishandling and preventive role of Klotho in mice to its potential mortality prediction in human. Translational Research, 2022, 243, 60-77.	5.0	5
18	Translational science in albuminuria: a new view of de novo albuminuria under chronic RAS suppression. Clinical Science, 2018, 132, 739-758.	4.3	4

#	Article	IF	CITATIONS
19	Analysis of Global Oxidative Status Using Multimarker Scores Reveals a Specific Association Between Renal Dysfunction and Diuretic Therapy in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1198-1205.	3.6	4
20	The endless story of markers of renal function and cardiovascular risk. European Heart Journal, 2019, 40, 3494-3495.	2.2	3
21	Variations in Circulating Active MMP-9 Levels during Renal Replacement Therapy. Biomolecules, 2020, 10, 505.	4.0	3
22	Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. Nefrologia, 2022, 42, 519-530.	0.4	1
23	Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, , .	3.0	0
24	On the need of the simultaneous control of arterial hypertension and diabetes mellitus. Journal of Clinical Hypertension, 2020, 22, 221-222.	2.0	0